The V-Twin system (Dade Behring Laboratories): A useful tool for immunosuppressive drug monitoring

Transplantation Proceedings

Volumn 37, Issue 1, 2005, Pages 167-171

  Elaerts, S ^a   Olejnik, Y ^a   Bonardet, A ^a   Garrigue, V ^a   Mourad, G ^a   Cristol, J P ^a   Dupuy, A M ^a  

^a LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACCURACY; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DOSE RESPONSE; DRUG EXPOSURE; DRUG MONITORING; HUMAN; MAJOR CLINICAL STUDY; MEDICAL TECHNOLOGY; NEPHROTOXICITY; PRIORITY JOURNAL; TRANSPLANTATION;

EID: 16244398880     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.12.192     Document Type: Conference Paper

References (16)

1. E. Cole, N. Maham, C. Cardella Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients Transplantation 75 2003 2086
2. F. Citterio, M.C. Scata, M.T. Borzi C2 single point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients Transplant Proc 33 2001 3133
3. G. Einecke, I. Mai, L. Fritsche The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression Nephrol Dial Transplant 19 2004 215
4. M. Cantarovich, J. Barkun, N. Giannetti History of C2 monitoring in heart and liver transplant patients treated with cyclosporine microemulsion Transplant Proc 36 suppl 2 2004 442S
5. B. Royer, S. Davani, M. Berard Therapeutic drug monitoring of mycophenolate mofetil, sirolimus and cyclosporine at C2 Ann Biol Clin (Paris) 61 2003 251
6. B.M. Meiser, M. Pfeiffer, D. Schmidt Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring J Heart Lung Transplant 18 1999 143
7. T. van Gelder, L.B. Hilbrands, Y. Vanrenterghem A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation Transplantation 68 1999 261
8. A. Vassault, M. Baud, M. Castanier Recommendations for a comparison of techniques. Document F, stage 3 Ann Biol Clin (Paris) 50 1992 727
9. J.M. Hows, J.M. Smith In vitro stability of cyclosporine A J Clin Pathol 36 1983 720
10. J.L. Rudy, J. Rutledge Preparation and optimal storage of a whole-blood control pool for cyclosporine A Clin Chem 32 1986 2294
11. J.M. Bland, D.G. Altman Measuring agreement in method comparison studies Stat Methods Med Res 8 1999 135
12. S. Hollis Analysis of method comparison studies Ann Clin Biochem 33 1996 1
13. M. Oellerich, V.W. Armstrong, B. Kahan Lake Louise Consensus Conference on cyclosporine monitoring in organ transplantation: report of the consensus panel Ther Drug Monit 17 1995 642
14. M.H. Yamani, R.C. Starling, M. Goormastic The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection Transplantation 69 2000 2326
15. L.M. Shaw, T. Pawinski, M. Korecka Monitoring of mycophenolic acid in clinical transplantation Ther Drug Monit 24 2002 68
16. L.M. Shaw, A. Nawrocki, M. Korecka Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations Ther Drug Monit 26 2004 347